KB-1240

Anetumab

12241

Home » Anetumab

Background of Anetumab

Mesothelin (MSLN) is a differentiative antigen that is highly expressed in several human tumors, including mesothelioma, ovarian, and pancreatic cancers. As MSLN is overexpressed only in tumor tissues and not in adjacent normal tissues in pancreatic cancer, and is closely associated with tumor progression and migration, it has been proven to be a promising cancer biomarker and an effective target for cancer-targeted therapy.Modification with an anti-MSLN antibody would improve the targeting efficiency of diagnostic imaging agents and the drug-delivery system towards the MSLN-overexpressing pancreatic tumors.

Specifications

Catalog Number	KB-1240
Antibody Name	Anetumab
Isotype	Human IgG1,lambda
FC Muations	Wild Type
Target	MSLN
Species Reactivity	Human
Host Cell Line	EXPI CHO
Purification Method	Affinity purified
Concentration	>2 mg/mL
Formulation	50 mM sodium citrate,150mM NaCl,pH5.5
Purity	>95% by SDS-PAGE and SEC-HPLC
Validation	ELISA \| FACS
Endotoxin Level	<0.2 EU/mg as determined by the LAL method
Sterility	0.2μm filtered
Storage	It is recommended that the protein should be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Stability	Stable for twelve months from date of receipt when stored at -20°C to -80°C;Stored at 2-8°C for one month without detectable loss of activity.

Characterization

Application

References

Argani P, Iacobuzio-Donahue C, Ryu B, et al. Mesothelin is overex-pressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). Clin Cancer Res. 2001;7:3862-3862.
Ordóñez NG. Application of mesothelin immunostaining in tumor diagnosis. Am J Surg Pathol. 2003;27:1418-1428.
Roe OD, Creaney J, Lundgren S, et al. Mesothelin-related predictive and prognostic factors in malignant mesothelioma: a nested case-control study. Lung Cancer. 2008;61:235-243.
Hassan R, Bera T, Pastan I. Mesothelin: a new target for immunotherapy. Clin Cancer Res. 2004;10(12 Pt 1):3937-3942.7.